{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:48:59Z","timestamp":1787028539148,"version":"build-2736575974"},"reference-count":96,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2024,5,25]],"date-time":"2024-05-25T00:00:00Z","timestamp":1716595200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004704","name":"National Research Council of Thailand","doi-asserted-by":"publisher","award":["N42A650352"],"award-info":[{"award-number":["N42A650352"]}],"id":[{"id":"10.13039\/501100004704","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004704","name":"National Research Council of Thailand","doi-asserted-by":"publisher","award":["MU-SRF-RS-05A\/67"],"award-info":[{"award-number":["MU-SRF-RS-05A\/67"]}],"id":[{"id":"10.13039\/501100004704","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004156","name":"Mahidol University","doi-asserted-by":"publisher","award":["N42A650352"],"award-info":[{"award-number":["N42A650352"]}],"id":[{"id":"10.13039\/501100004156","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004156","name":"Mahidol University","doi-asserted-by":"publisher","award":["MU-SRF-RS-05A\/67"],"award-info":[{"award-number":["MU-SRF-RS-05A\/67"]}],"id":[{"id":"10.13039\/501100004156","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Faculty of Pharmacy, Chiang Mai University","award":["N42A650352"],"award-info":[{"award-number":["N42A650352"]}]},{"name":"Faculty of Pharmacy, Chiang Mai University","award":["MU-SRF-RS-05A\/67"],"award-info":[{"award-number":["MU-SRF-RS-05A\/67"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Cardiovascular diseases (CVDs), particularly heart failure, are major contributors to early mortality globally. Heart failure poses a significant public health problem, with persistently poor long-term outcomes and an overall unsatisfactory prognosis for patients. Conventionally, treatments for heart failure have focused on lowering blood pressure; however, the development of more potent therapies targeting hemodynamic parameters presents challenges, including tolerability and safety risks, which could potentially restrict their clinical effectiveness. Adenosine has emerged as a key mediator in CVDs, acting as a retaliatory metabolite produced during cellular stress via ATP metabolism, and works as a signaling molecule regulating various physiological processes. Adenosine functions by interacting with different adenosine receptor (AR) subtypes expressed in cardiac cells, including A1AR, A2AAR, A2BAR, and A3AR. In addition to A1AR, A3AR has a multifaceted role in the cardiovascular system, since its activation contributes to reducing the damage to the heart in various pathological states, particularly ischemic heart disease, heart failure, and hypertension, although its role is not as well documented compared to other AR subtypes. Research on A3AR signaling has focused on identifying the intricate molecular mechanisms involved in CVDs through various pathways, including Gi or Gq protein-dependent signaling, ATP-sensitive potassium channels, MAPKs, and G protein-independent signaling. Several A3AR-specific agonists, such as piclidenoson and namodenoson, exert cardioprotective impacts during ischemia in the diverse animal models of heart disease. Thus, modulating A3ARs serves as a potential therapeutic approach, fueling considerable interest in developing compounds that target A3ARs as potential treatments for heart diseases.<\/jats:p>","DOI":"10.3390\/ijms25115763","type":"journal-article","created":{"date-parts":[[2024,5,27]],"date-time":"2024-05-27T10:12:27Z","timestamp":1716804747000},"page":"5763","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Adenosine A3 Receptor: From Molecular Signaling to Therapeutic Strategies for Heart Diseases"],"prefix":"10.3390","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-7112-337X","authenticated-orcid":false,"given":"Ratchanee","family":"Duangrat","sequence":"first","affiliation":[{"name":"Department of Pharmacology, Faculty of Science, Mahidol University, Bangkok 10400, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7851-2477","authenticated-orcid":false,"given":"Warisara","family":"Parichatikanond","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Faculty of Pharmacy, Mahidol University, Bangkok 10400, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wisinee","family":"Chanmahasathien","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, Faculty of Pharmacy, Chiang Mai University, Chiang Mai 50200, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3223-1551","authenticated-orcid":false,"given":"Supachoke","family":"Mangmool","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Care, Faculty of Pharmacy, Chiang Mai University, Chiang Mai 50200, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,5,25]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s40256-019-00345-5","article-title":"Adenosine and the cardiovascular system","volume":"19","author":"Reiss","year":"2019","journal-title":"Am. J. Cardiovasc. Drugs"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1152\/physrev.00049.2017","article-title":"Pharmacology of adenosine receptors: The state of the art","volume":"98","author":"Borea","year":"2018","journal-title":"Physiol. Rev."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.2174\/1381612805666230112212126","article-title":"Adenosine and ischemic preconditioning","volume":"5","author":"Liang","year":"1999","journal-title":"Curr. Pharm. Des."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/S0008-6363(97)00160-0","article-title":"Evidence for a role for both the adenosine A1 and A3 receptors in protection of isolated human atrial muscle against simulated ischaemia","volume":"36","author":"Carr","year":"1997","journal-title":"Cardiovasc. Res."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s11302-011-9274-3","article-title":"Partial adenosine A1 receptor agonists for cardiovascular therapies","volume":"8","author":"Leineweber","year":"2012","journal-title":"Purinergic Signal."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s10741-015-9522-7","article-title":"Partial adenosine A1 receptor agonism: A potential new therapeutic strategy for heart failure","volume":"21","author":"Greene","year":"2016","journal-title":"Heart Fail. Rev."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"18","DOI":"10.2174\/1573403X12666160111125116","article-title":"Adenosine A3 receptor: A promising therapeutic target in cardiovascular disease","volume":"12","author":"Nishat","year":"2016","journal-title":"Curr. Cardiol. Rev."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1161\/CIRCULATIONAHA.108.810101","article-title":"Adenosine A3 receptor and cardioprotection: Enticing, enigmatic, elusive","volume":"118","author":"Rothermel","year":"2008","journal-title":"Circulation"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.pharmthera.2013.06.002","article-title":"Cardiovascular adenosine receptors: Expression, actions and interactions","volume":"140","author":"Headrick","year":"2013","journal-title":"Pharmacol. Ther."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.pharmthera.2007.09.002","article-title":"The A3 adenosine receptor: An enigmatic player in cell biology","volume":"117","author":"Gessi","year":"2008","journal-title":"Pharmacol. Ther."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Garcia-Garcia, L., Olle, L., Martin, M., Roca-Ferrer, J., and Mu\u00f1oz-Cano, R. (2021). Adenosine signaling in mast cells and allergic diseases. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22105203"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Pasquini, S., Contri, C., Borea, P.A., Vincenzi, F., and Varani, K. (2021). Adenosine and inflammation: Here, there and everywhere. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22147685"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.drudis.2011.10.007","article-title":"Pharmacological and therapeutic effects of A3 adenosine receptor agonists","volume":"17","author":"Fishman","year":"2012","journal-title":"Drug Discov. Today"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"10365","DOI":"10.1073\/pnas.90.21.10365","article-title":"Molecular cloning and characterization of the human A3 adenosine receptor","volume":"90","author":"Salvatore","year":"1993","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1124\/pr.113.008540","article-title":"The A3 adenosine receptor: History and perspectives","volume":"67","author":"Borea","year":"2015","journal-title":"Pharmacol. Rev."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1111\/j.1365-2885.2006.00748.x","article-title":"Cloning and pharmacological characterization of the equine adenosine A3 receptor","volume":"29","author":"Brandon","year":"2006","journal-title":"J. Vet. Pharmacol. Ther."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0168-0102(97)00073-4","article-title":"Cloning, characterisation and chromosomal assignment of the human adenosine A3 receptor (ADORA3) gene","volume":"29","author":"Atkinson","year":"1997","journal-title":"Neurosci. Res."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.yjmcc.2010.01.018","article-title":"A3 adenosine receptor activation during reperfusion reduces infarct size through actions on bone marrow-derived cells","volume":"49","author":"Ge","year":"2010","journal-title":"J. Mol. Cell. Cardiol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s10557-013-6500-y","article-title":"Caspase inhibition via A3 adenosine receptors: A new cardioprotective mechanism against myocardial infarction","volume":"28","author":"Hussain","year":"2014","journal-title":"Cardiovasc. Drugs Ther."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.yjmcc.2005.06.001","article-title":"Adenosine triggers preconditioning through MEK\/ERK1\/2 signalling pathway during hypoxia\/reoxygenation in neonatal rat cardiomyocytes","volume":"39","author":"Germack","year":"2005","journal-title":"J. Mol. Cell. Cardiol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.ejphar.2017.08.011","article-title":"Attenuation of Sunitinib-induced cardiotoxicity through the A3 adenosine receptor activation","volume":"814","author":"Sandhu","year":"2017","journal-title":"Eur. J. Pharmacol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.bcp.2009.08.010","article-title":"Adenosine A3 receptor-mediated cardioprotection against doxorubicin-induced mitochondrial damage","volume":"79","author":"Emanuelov","year":"2010","journal-title":"Biochem. Pharmacol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"H49","DOI":"10.1152\/ajpheart.2002.282.1.H49","article-title":"Comparison of the vascular effects of adenosine in isolated mouse heart and aorta","volume":"282","author":"Talukder","year":"2002","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1161\/01.RES.78.4.627","article-title":"Adenosine-induced vasoconstriction in vivo: Role of the mast cell and A3 adenosine receptor","volume":"78","author":"Shepherd","year":"1996","journal-title":"Circ. Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/aps.2010.18","article-title":"Stimulation of the adenosine A3 receptor reverses vascular hyporeactivity after hemorrhagic shock in rats","volume":"31","author":"Zhou","year":"2010","journal-title":"Acta Pharmacol. Sin."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"H1562","DOI":"10.1152\/ajpheart.00335.2002","article-title":"Overexpression of A3 adenosine receptors decreases heart rate, preserves energetics, and protects ischemic hearts","volume":"283","author":"Cross","year":"2002","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1161\/01.RES.0000028007.91385.EE","article-title":"Gene dosage-dependent effects of cardiac-specific overexpression of the A3 adenosine receptor","volume":"91","author":"Black","year":"2002","journal-title":"Circ. Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1161\/CIRCULATIONAHA.108.788307","article-title":"Adenosine A3 receptor deficiency exerts unanticipated protective effects on the pressure-overloaded left ventricle","volume":"118","author":"Lu","year":"2008","journal-title":"Circulation"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Ho, M.F., Low, L.M., and Rose\u2019Meyer, R.B. (2016). Pharmacology of the adenosine A3 receptor in the vasculature and essential hypertension. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0150021"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/0165-6147(94)90011-6","article-title":"Cloned adenosine A3 receptors: Pharmacological properties, species differences and receptor functions","volume":"15","author":"Linden","year":"1994","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.yjmcc.2012.08.003","article-title":"Adenosine A(3) receptorinduced proliferation of primary human coronary smooth muscle cells involving the induction of early growth response genes","volume":"53","author":"Hinze","year":"2012","journal-title":"J. Mol. Cell. Cardiol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1007\/s00395-013-0340-6","article-title":"Novel effects of adenosine receptors on pericellular hyaluronan matrix: Implications for human smooth muscle cell phenotype and interactions with monocytes during atherosclerosis","volume":"108","author":"Grandoch","year":"2013","journal-title":"Basic. Res. Cardiol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/S0925-4439(99)00111-8","article-title":"A role for the A3 adenosine receptor in determining tissue levels of cAMP and blood pressure: Studies in knock-out mice","volume":"1500","author":"Zhao","year":"2000","journal-title":"Biochim. Et Biophys. Acta (BBA)-Mol. Basis Dis."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Tarifa, C., Jim\u00e9nez-S\u00e1bado, V., Franco, R., Montiel, J., Guerra, J., Ciruela, F., and Hove-Madsen, L. (2023). Expression and impact of adenosine A3 receptors on calcium homeostasis in human right atrium. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24054404"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/S0008-6363(96)00240-4","article-title":"Selective adenosine A3 receptor stimulation reduces ischemic myocardial injury in the rabbit heart","volume":"33","author":"Tracey","year":"1997","journal-title":"Cardiovasc. Res."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.pharmthera.2007.02.004","article-title":"Adenosinergic cardioprotection: Multiple receptors, multiple pathways","volume":"114","author":"Peart","year":"2007","journal-title":"Pharmacol. Ther."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Vincenzi, F., Pasquini, S., Contri, C., Cappello, M., Nigro, M., Travagli, A., Merighi, S., Gessi, S., Borea, P.A., and Varani, K. (2023). Pharmacology of adenosine receptors: Recent advancements. Biomolecules, 13.","DOI":"10.3389\/fphar.2022.1030895"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1517\/13543784.2011.573785","article-title":"Investigational A3 adenosine receptor targeting agents","volume":"20","author":"Pacher","year":"2011","journal-title":"Expert. Opin. Investig. Drugs."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"4826","DOI":"10.1073\/pnas.97.9.4826","article-title":"Conditional expression of a Gi-coupled receptor causes ventricular conduction delay and a lethal cardiomyopathy","volume":"97","author":"Redfern","year":"2000","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/6165","article-title":"Conditional expression and signaling of a specifically designed Gi-coupled receptor in transgenic mice","volume":"17","author":"Redfern","year":"1999","journal-title":"Nat. Biotechnol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.yjmcc.2004.08.001","article-title":"Activation of protein kinase B by adenosine A1 and A3 receptors in newborn rat cardiomyocytes","volume":"37","author":"Germack","year":"2004","journal-title":"J. Mol. Cell. Cardiol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"H328","DOI":"10.1152\/ajpheart.00453.2004","article-title":"Pharmacological preconditioning with resveratrol: Role of CREB-dependent Bcl-2 signaling via adenosine A3 receptor activation","volume":"288","author":"Das","year":"2005","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1124\/jpet.105.084285","article-title":"Resveratrol-mediated activation of cAMP response element-binding protein through adenosine A3 receptor by Akt-dependent and-independent pathways","volume":"314","author":"Das","year":"2005","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1124\/mol.58.3.477","article-title":"Human adenosine A1, A2A, A2B, and A3 receptors expressed in Chinese hamster ovary cells all mediate the phosphorylation of extracellular-regulated kinase 1\/2","volume":"58","author":"Schulte","year":"2000","journal-title":"Mol. Pharmacol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1124\/mol.62.5.1137","article-title":"Signaling pathway from the human adenosine A3 receptor expressed in Chinese hamster ovary cells to the extracellular signal-regulated kinase 1\/2","volume":"62","author":"Schulte","year":"2002","journal-title":"Mol. Pharmacol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s00395-012-0281-5","article-title":"The mechanism of beta-adrenergic preconditioning: Roles for adenosine and ROS during triggering and mediation","volume":"107","author":"Salie","year":"2012","journal-title":"Basic Res. Cardiol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s11010-010-0568-5","article-title":"Adenosine A1 and A3 receptor agonists reduce hypoxic injury through the involvement of p38 MAPK","volume":"345","author":"Hochhauser","year":"2010","journal-title":"Mol. Cell Biochem."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"19516","DOI":"10.1074\/jbc.M413772200","article-title":"A3 adenosine receptor activation inhibits cell proliferation via phosphatidylinositol 3-kinase\/Akt-dependent inhibition of the extracellular signal-regulated kinase 1\/2 phosphorylation in A375 human melanoma cells","volume":"280","author":"Merighi","year":"2005","journal-title":"J. Biol. Chem."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/j.1476-5381.2010.00667.x","article-title":"Expression and functional role of adenosine receptors in regulating inflammatory responses in human synoviocytes","volume":"160","author":"Varani","year":"2010","journal-title":"Br. J. Pharmacol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1124\/jpet.106.101477","article-title":"N6-(3-iodobenzyl)-adenosine-5\u2032-N-methylcarboxamide confers cardioprotection at reperfusion by inhibiting mitochondrial permeability transition pore opening via glycogen synthase kinase 3\u03b2","volume":"318","author":"Park","year":"2006","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Kutryb-Zaj\u0105c, B., Kawecka, A., Nasadiuk, K., Braczko, A., Stawarska, K., Caiazzo, E., Kosza\u0142ka, P., and Cicala, C. (2023). Drugs targeting adenosine signaling pathways: A current view. Biomed. Pharmacother., 165.","DOI":"10.1016\/j.biopha.2023.115184"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"H434","DOI":"10.1152\/ajpheart.00095.2003","article-title":"Protein kinase C-\u03b4 mediates adenosine A3 receptor-induced delayed cardioprotection in mouse","volume":"285","author":"Zhao","year":"2003","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s11010-006-9118-6","article-title":"Modulation of cardiac sarcoplasmic reticulum calcium release by aenosine: A protein kinase C-dependent pathway","volume":"288","author":"Ghelardoni","year":"2006","journal-title":"Mol. Cell. Biochem."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1161\/CIRCULATIONAHA.110.952481","article-title":"Aldehyde dehydrogenase activation prevents reperfusion arrhythmias by inhibiting local renin release from cardiac mast cells","volume":"122","author":"Koda","year":"2010","journal-title":"Circulation"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"11941","DOI":"10.1523\/JNEUROSCI.1183-11.2011","article-title":"Oxygen\/glucose deprivation induces a reduction in synaptic AMPA receptors on hippocampal CA3 neurons mediated by mGluR1 and adenosine A3 receptors","volume":"31","author":"Dennis","year":"2011","journal-title":"J. Neurosci."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/S0008-6363(98)00112-6","article-title":"Selective activation of adenosine A3 receptors with N 6-(3-chlorobenzyl)-5\u2032-N-methylcarboxamidoadenosine (CB-MECA) provides cardioprotection via KATP channel activation","volume":"40","author":"Tracey","year":"1998","journal-title":"Cardiovasc. Res."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1124\/jpet.107.127480","article-title":"The A3 adenosine receptor agonist CP-532,903 [N6-(2, 5-dichlorobenzyl)-3\u2032-aminoadenosine-5\u2032-N-methylcarboxamide] protects against myocardial ischemia\/reperfusion injury via the sarcolemmal ATP-sensitive potassium channel","volume":"324","author":"Wan","year":"2008","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1096\/fj.03-0592fje","article-title":"Role of direct RhoA-phospholipase D interaction in mediating adenosine-induced protection from cardiac ischemia","volume":"18","author":"Mozzicato","year":"2004","journal-title":"FASEB J."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/nrd1983","article-title":"Adenosine receptors as therapeutic targets","volume":"5","author":"Jacobson","year":"2006","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.bcp.2019.01.022","article-title":"Ability of CP-532,903 to protect mouse hearts from ischemia\/reperfusion injury is dependent on expression of A3 adenosine receptors in cardiomyoyctes","volume":"163","author":"Wan","year":"2019","journal-title":"Biochem. Pharmacol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"H2780","DOI":"10.1152\/ajpheart.00411.2003","article-title":"Novel N 6-substituted adenosine 5\u2032-N-methyluronamides with high selectivity for human adenosine A3 receptors reduce ischemic myocardial injury","volume":"285","author":"Tracey","year":"2003","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1161\/01.RES.80.6.800","article-title":"Selective activation of A3 adenosine receptors with N 6-(3-iodobenzyl) adenosine-5\u2032-N-methyluronamide protects against myocardial stunning and infarction without hemodynamic changes in conscious rabbits","volume":"80","author":"Auchampach","year":"1997","journal-title":"Circ. Res."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1021\/jm0255724","article-title":"3\u2018-Aminoadenosine-5\u2018-uronamides: Discovery of the first highly selective agonist at the human adenosine A3 receptor","volume":"46","author":"Deninno","year":"2003","journal-title":"J. Med. Chem."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1093\/cvr\/28.7.1057","article-title":"Evidence that the adenosine A3 receptor may mediate the protection afforded by preconditioning in the isolated rabbit heart","volume":"28","author":"Liu","year":"1994","journal-title":"Cardiovas. Res."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1124\/jpet.106.111351","article-title":"Cl-IB-MECA [2-Chloro-N6-(3-iodobenzyl) adenosine-5\u2032-N-methylcarboxamide] reduces ischemia\/reperfusion injury in mice by activating the A3 adenosine receptor","volume":"319","author":"Ge","year":"2006","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0014-2999(01)01611-9","article-title":"Preconditioning of rat hearts by adenosine A1 or A3 receptor activation","volume":"441","author":"Out","year":"2002","journal-title":"Eur. J. Pharmacol."},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Procopio, M.C., Lauro, R., Nasso, C., Carerj, S., Squadrito, F., Bitto, A., Di, B.G., Micari, A., Irrera, N., and Costa, F. (2021). Role of adenosine and purinergic receptors in myocardial infarction: Focus on different signal transduction pathways. Biomedicines, 9.","DOI":"10.3390\/biomedicines9020204"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s003950170031","article-title":"Protection of IB-MECA against myocardial stunning in conscious rabbits is not mediated by the A1 adenosine receptor","volume":"96","author":"Kodani","year":"2001","journal-title":"Basic. Res. Cardiol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.cardiores.2003.09.031","article-title":"Protein kinase activation and myocardial ischemia\/reperfusion injury","volume":"61","author":"Armstrong","year":"2004","journal-title":"Cardiovasc. Res."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S0008-6363(01)00424-2","article-title":"Effects of A3 adenosine receptor activation and gene knock-out in ischemic-reperfused mouse heart","volume":"53","author":"Harrison","year":"2002","journal-title":"Cardiovas. Res."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1006\/jmcc.2001.1338","article-title":"Targeted deletion of the A3 adenosine receptor confers resistance to myocardial ischemic injury and does not prevent early preconditioning","volume":"33","author":"Guo","year":"2001","journal-title":"J. Mol. Cell Cardiol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"H1751","DOI":"10.1152\/ajpheart.2001.281.4.H1751","article-title":"Targeted deletion of A3 adenosine receptors improves tolerance to ischemia-reperfusion injury in mouse myocardium","volume":"281","author":"Cerniway","year":"2001","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1006\/jmcc.2001.1387","article-title":"Activation of A3 adenosine receptor protects against doxorubicin-induced cardiotoxicity","volume":"33","author":"Shneyvays","year":"2001","journal-title":"J. Mol. Cell. Cardiol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"724320","DOI":"10.3389\/fphar.2021.724320","article-title":"Pharmacological tuning of adenosine signal nuances underlying heart failure with preserved ejection fraction","volume":"12","year":"2021","journal-title":"Front. pharmacol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1161\/HYPERTENSIONAHA.108.110833","article-title":"Ecto-5\u2032-nucleotidase deficiency exacerbates pressure-overload\u2013induced left ventricular hypertrophy and dysfunction","volume":"51","author":"Xu","year":"2008","journal-title":"Hypertension"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.cardiores.2004.02.004","article-title":"Gene dose-dependent atrial arrhythmias, heart block, and brady-cardiomyopathy in mice overexpressing A3 adenosine receptors","volume":"62","author":"Fabritz","year":"2004","journal-title":"Cardiovas. Res."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"e003868","DOI":"10.1161\/JAHA.116.003868","article-title":"Genetic abrogation of adenosine A3 receptor prevents uninephrectomy and high salt\u2013induced hypertension","volume":"5","author":"Yang","year":"2016","journal-title":"J. Am. Heart Assoc."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"H3448","DOI":"10.1152\/ajpheart.00764.2007","article-title":"Involvement of COX-1 in A3 adenosine receptor-mediated contraction through endothelium in mice aorta","volume":"293","author":"Ansari","year":"2007","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1124\/jpet.111.180828","article-title":"NADPH oxidase pathway is involved in aortic contraction induced by A3 adenosine receptor in mice","volume":"338","author":"Ansari","year":"2011","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1002\/jcb.20122","article-title":"A3 adenosine receptor deficiency does not influence atherogenesis","volume":"92","author":"Jones","year":"2004","journal-title":"J. Cell. Biochem."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"186","DOI":"10.4330\/wjc.v3.i6.186","article-title":"Ischemia\/reperfusion injury and cardioprotective mechanisms: Role of mitochondria and reactive oxygen species","volume":"3","author":"Perrelli","year":"2011","journal-title":"World J. Cardiol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1007\/s00395-023-00992-5","article-title":"The RISK pathway leading to mitochondria and cardioprotection: How everything started","volume":"118","author":"Yellon","year":"2023","journal-title":"Basic. Res. Cardiol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1097\/00001813-200206000-00001","article-title":"A3 adenosine receptor as a target for cancer therapy","volume":"13","author":"Fishman","year":"2002","journal-title":"Anti-Cancer Drugs"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1016\/S0140-6736(20)32511-3","article-title":"Non-alcoholic fatty liver disease","volume":"397","author":"Powell","year":"2021","journal-title":"Lancet"},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Pouwels, S., Sakran, N., Graham, Y., Leal, A., Pintar, T., Yang, W., Kassir, R., Signhal, R., Mahawar, K., and Ramnarain, D. (2022). Non-alcoholic fatty liver disease (NAFLD): A review of pathophysiology, clinical management and effects of weight loss. BMC Endocr. Disord., 22.","DOI":"10.1186\/s12902-022-00980-1"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/s41575-019-0186-y","article-title":"A global view of hepatocellular carcinoma: Trends, risk, prevention and management","volume":"16","author":"Yang","year":"2019","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"4472","DOI":"10.1158\/1078-0432.CCR-03-0651","article-title":"The A3 adenosine receptor is highly expressed in tumor versus normal cells: Potential target for tumor growth inhibition","volume":"10","author":"Madi","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Fishman, P. (2022). Drugs targeting the A3 adenosine receptor: Human clinical study data. Molecules, 27.","DOI":"10.3390\/molecules27123680"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1111\/apt.16664","article-title":"Randomised clinical trial: A phase 2 double-blind study of namodenoson in non-alcoholic fatty liver disease and steatohepatitis","volume":"54","author":"Safadi","year":"2021","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1053\/j.gastro.2004.09.014","article-title":"Hepatocellular carcinoma in cirrhosis: Incidence and risk factors","volume":"127","author":"Fattovich","year":"2004","journal-title":"Gastroenterology"},{"key":"ref_91","doi-asserted-by":"crossref","unstructured":"Stemmer, S.M., Manojlovic, N.S., Marinca, M.V., Petrov, P., Cherciu, N., Ganea, D., Ciuleanu, T.E., Pusca, I.A., Beg, M.S., and Purcell, W.T. (2021). Namodenoson in advanced hepatocellular carcinoma and Child\u2013Pugh B cirrhosis: Randomized placebo-controlled clinical trial. Cancers, 13.","DOI":"10.3390\/cancers13020187"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"534","DOI":"10.5414\/CPP42534","article-title":"Tolerability, pharmacokinetics and concentration-dependent hemodynamic effects of oral CF101, an A3 adenosine receptor agonist, in healthy young men","volume":"42","author":"Clark","year":"2004","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"ref_93","first-page":"931","article-title":"Treatment of plaque-type psoriasis with oral CF101: Data from a phase II\/III multicenter, randomized, controlled trial","volume":"15","author":"David","year":"2016","journal-title":"J. Drugs Dermatol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1111\/jdv.19811","article-title":"Efficacy and safety of piclidenoson in plaque psoriasis: Results from a randomized phase 3 clinical trial (COMFORT-1)","volume":"38","author":"Papp","year":"2024","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"Mangmool, S., Duangrat, R., Parichatikanond, W., and Kurose, H. (2023). New therapeutics for heart failure: Focusing on cGMP signaling. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241612866"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"34","DOI":"10.3389\/fcvm.2020.00034","article-title":"Therapeutic targets for the treatment of cardiac fibrosis and cancer: Focusing on TGF-\u03b2 signaling","volume":"7","author":"Parichatikanond","year":"2020","journal-title":"Front. Cardiovasc. Med."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/11\/5763\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:48:48Z","timestamp":1760107728000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/11\/5763"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,25]]},"references-count":96,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2024,6]]}},"alternative-id":["ijms25115763"],"URL":"https:\/\/doi.org\/10.3390\/ijms25115763","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,25]]}}}